GlassScriptPhysician profile
Sakeba Naim Issa
NPI 1164475505
$3,162.36
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $833 · 2021: $22.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $447.04 | 2019-2020 | |
| Horizon Therapeutics Plc | $418.91 | 2019-2021 | |
| Abbvie INC. | $397.58 | 2019-2020 | |
| Pfizer INC. | $347.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $284.94 | 2019-2020 | |
| Janssen Biotech, INC. | $214.31 | 2019-2020 | |
| Lilly USA, LLC | $192.36 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $141.92 | 2019-2020 | |
| Celgene Corporation | $139.68 | 2019 | |
| Genzyme Corporation | $108.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2019 | |
| Genentech USA, INC. | $62.59 | 2019 | |
| Mallinckrodt Enterprises LLC | $61.64 | 2019 | |
| Antares Pharma, INC. | $47.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.14 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $38.88 | 2019 | |
| Mallinckrodt Hospital Products INC. | $29.38 | 2020 | |
| Sebela Pharmaceuticals INC. | $28.19 | 2019 | |
| Hikma Pharmaceuticals USA | $28.19 | 2019 | |
| Sobi, INC | $19.67 | 2019 | |
| Merck Sharp & Dohme LLC | $18.76 | 2019 | |
| Radius Health, INC. | $14.55 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sakeba Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.